SCHEDULE 13G: Matrix Capital Management Discloses 5.7% Passive Stake in Maze Therapeutics

Matrix Capital Management Company, LP and David E. Goel have jointly disclosed a passive beneficial ownership of 5.7% in Maze Therapeutics, Inc., totaling 2,486,184 common shares.

Summary

• Matrix Capital Management Company, LP and David E. Goel (the "Reporting Persons") have filed a Schedule 13G with the SEC.
• The Reporting Persons collectively beneficially own 2,486,184 shares of Maze Therapeutics, Inc. common stock.
• This ownership represents 5.7% of the outstanding common stock of Maze Therapeutics, Inc.
• The shares are held by Matrix Capital Management Master Fund, LP, with Matrix Capital Management Company, LP acting as the investment adviser and David E. Goel as its Managing General Partner.
• The filing indicates that the Reporting Persons have shared voting and shared dispositive power over all 2,486,184 reported shares.
• The 5.7% ownership percentage is calculated based on an aggregate of 43,796,057 shares of Maze Therapeutics, Inc. common stock outstanding as of March 25, 2025, as reported in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The filing is a standard regulatory disclosure of a passive beneficial ownership stake. While not directly indicative of company performance, the disclosure of a significant stake by a reputable investment firm can be viewed as a neutral to slightly positive signal of investor confidence.

Positives

• Disclosure of a significant passive stake by Matrix Capital Management, a notable investment firm, potentially signaling confidence in Maze Therapeutics, Inc.

Negatives

• None directly indicated by the nature of this passive ownership filing.

Risks

• The filing includes a disclaimer that it should not be construed as an admission that any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The filing is a disclosure by the Reporting Persons (Matrix Capital Management and David E. Goel) and does not contain direct management comments from Maze Therapeutics, Inc.

Industry Context

This filing indicates a significant passive investment by a capital management firm in a therapeutics company, which is common practice within the investment landscape for the biotechnology and pharmaceutical sectors. It reflects an investment decision by Matrix Capital Management rather than a direct industry trend.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not contain information suitable for comparison to industry-specific performance benchmarks or competitor results.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which may be interpreted as a vote of confidence.
• Company: Becomes aware of a new significant passive shareholder, which could influence future investor relations strategies.

Next Steps

• The Reporting Persons will file amendments to this Schedule 13G if there are material changes to their beneficial ownership or the nature of their investment.

Key Dates

Keywords

Maze Therapeutics, Matrix Capital Management, David E. Goel, Schedule 13G, beneficial ownership, common stock, investment, institutional investor, biotechnology, pharmaceuticals